Alnylam Pharmaceuticals Net Loss Widens In Q2

Alnylam Pharmaceuticals Inc. (ALNY) Thursday reported a net loss for the second quarter that widened from the prior year. The quarterly loss was $277.40 million or $2.29 per share, wider than $189.56 million or $1.61 per share a year ago.

On an adjusted basis, loss was $245.83 million or $2.03 per share. Wall Street analysts estimated a loss of $1.63 per share.

Revenue for the quarter gained 1.9 percent to $224.82 million from $220.55 million a year ago.

Further, the company updated that it expects to report positive results from the Apollo-B Phase 3 study of patrisiran in ATTR Amyloidosis patients with cardiomyopathy in next three weeks. The company will present the results from the Phase 2 study of cemdisiran in patients with IgAN at the 18th European Meeting on Complement in Human Disease on August 26-29, 2022 in Bern, Switzerland.

In Mid and late 2022, the pharma company will launch vutrisiran in the EU, assuming favourable adoption of the CHMP opinion.

Further, the company noted that Vir Biotechnology plans to report additional results from its Phase 2 study of ALN-HBV02 in combination with VIR-3434 in patients with chronic HBV infection in the second half of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ford Motor is increasing the entry-level price of its electric F-150 Lightning pickup citing rising costs and supply chain issues amid increasing demand. This is the second price hike after a recent increase in August. The starting price of the 2023 model year pickup will be raised by $5,000 by October 24, reports said citing an email statement. Constellation Brands, Inc. (STZ) said it delivered another quarter of strong business performance. Beer Business achieved double-digit net sales growth for the quarter, while Wine and Spirits net sales rose 1%. The solid top-line performance of its Beer and Wine and Spirits Businesses in the first half... Tyson Foods announced its "OneTyson" plan, under which it will bring together corporate team members from three corporate locations in Illinois and South Dakota to its world headquarters in Arkansas. Team members from the corporate locations of Chicago, Downers Grove in Illinois, and Dakota Dunes area in South Dakota are expected to begin the phased relocation in early 2023 to Springdale.
Follow RTT